Technologieangebote

We have developed a new method for improvement of cellulase and hemicellulase production in Trichoderma reesei by overexpression of a developmental regulator.

The present invention specifically provides a novel vaccine formulation
suitable for ocular immunization and provides a method for inducing a local and systemic immune response. The combination of the three components antigen & corpusculate bodies (eg.Bortedella pertussis (wBP)) & adjuvans showed the highest rise in IgA antibody titers in tears and sera when compared to other immunization groups. Immunization via the conjunctiva with TTd plus wBP and adjuvant resulted in a 33% survival rate of challenged mice compared to a 0% survival rate in non-immunized animals.

Die hier vorgestellt Weiterentwicklung ermöglicht die weitestgehende Mitnahme der Oberflächenschicht bei der Weichsedimentbeprobung per Schwerelot. Durch die Erzeugung eines Unterdruckes im Linerrohr wird der Kernfänger entlastet und ein besserer Probenhalt im Rohr gewährleistet.
Die beschriebene Verbesserung wird ermöglicht durch das Durchführen des Mantelrohres samt PVC-Liner durch den Gewichtssatz. Dabei sitzt der Verschluss mit der Unterdruckklappe direkt auf dem Liner. Die Neuerung der vorgestellten Erfindung bezieht sich direkt auf den konstruktiven Aufbau eines Schwerelotes. Bei üblichen Schwerelotausführungen wird an den Gewichtssatz, welcher das Eigengewicht den Eindringvorgang ausübt und gleichzeitig die Halterung für das Bergungsseil beinhaltet, von unten ein Probenrohr zur Aufnahme von Sedimenten angefügt. Die Weiterentwicklung sieht nun wie oben beschrieben eine Verbindung des Gewichtsatzes mit dem Probenrohr vor. Auf diese Weise kann eine komplette Probe mit Oberflächenschicht geborgen werden.

USE OF ERYTHROPOIETIN FOR THE TREATMENT OF
FRIEDREICH´S ATAXIA:
In addition to its neuro- and cardioprotective properties recombinant human erythropoietin (rhuEPO) significantly increases frataxin expression in primary lymphocytes from FApatients, and other cell types like neurons and primary human cardiac cells in vitro. (Sturm et.al 2005, Eur. J.Clin. Invest. 35(11):711-7) rhuEPO was successfully tested as a treatment for Friedreich`s ataxia in Phase IIa/IIb and dosefinding studies.

Pathological calcification processes in the human body are often the
beginning of a series of diseases which relate to organ systems such as the
vascular system of the heart, and kidney. As a consequence of metabolic
diseases such as diabetes, calcification processes can lead to severe
impairments of health or to death. Therefore, it is of scientific and
economical interest, to develop new approaches for quick and inexpensive
treatments of these diseases. Already known calcification biomarkers
provide an indication of occurring calcification processes but still can’t make a statement about triggering factors, which will be possible with our in vitro calcification model, CALCI-QUICK.

Researchers of the Medical University of Vienna have identified highly
active synthetic chalcones derived from the chalcone scaffold. These
cytotoxic compounds were found and developed by modifying the
chalcone lead structure concurrent with in vitro tests to evaluate their
cytotoxic potential in different cancer cell lines. Compounds were
thoroughly tested regarding their efficacy in inhibiting proliferation and
viability in cancer cell lines of the hematopoietic system. The combination of the new chalcone compound with the targeting agents, Idelalisib and Ibrutinib, which are novel compounds in the treatment of hematological malignancies, displayed higher cytotoxicity on CLL cells than Idelalisib and Ibrutinib alone.